Document is current
Any future updates will be listed below
-
Authors
Abellanas, Miguel Angel https://orcid.org/0000-0002-5680-1582
Basurco, Leyre https://orcid.org/0000-0001-6427-4359
Purnapatre, Maitreyee
Burgaletto, Chiara https://orcid.org/0000-0002-5517-8223
Castellani, Giulia
Colaiuta, Sarah Phoebeluc
Peralta-Ramos, Javier Maria https://orcid.org/0000-0001-9730-9001
Ibraheem, Angham
Murad, Sama
Antonello, Paola
Kovacs, Mariangeles
Androsova, Yuliya
Nathansohn, Bar
Partney, Hannah
Cahalon, Liora
Valdes-Mas, Rafael
Josephides, Joseph M. https://orcid.org/0000-0002-0256-0322
Salame, Tomer M.
Espelosin, Maria
Cuadrado-Tejedor, Mar
Garcia-Osta, Ana
Deczkowska, Aleksandra https://orcid.org/0000-0003-0844-4346
Schwartz, Michal https://orcid.org/0000-0003-4015-7507
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 16 July 2026
First Online: 8 September 2026
Ethics
Competing interests: M.S. is an inventor of the intellectual property that forms the basis for the development of PD-L1 immunotherapy for AD. All other authors declare no competing interests.
